|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1998-11-25
|
|
pubmed:abstractText |
Platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) is associated with angiogenesis and the progression of human ovarian cancer. The enzyme converts thymidine to thymine and 2'-deoxyribose-1-phosphate and can also metabolize the prodrug 5'-deoxy-5-fluorouridine (Furtulon) to 5-fluorouracil and 5'-deoxy-D-ribose-1-phosphate. The aim of this study was to obtain information about the activities of Furtulon in an established three-dimensional model of angiogenesis. The plan was to study partial and complete effects of Furtulon (in the absence and presence of PD-ECGF/TP or ovarian cancer cyst fluids) on the formation and destruction of microvessels from cultured segments of rat aorta in serum-free media. The endpoint was the number and form of microvessels compared with controls after 4, 7, 11, and 14 (and sometimes 17) days in culture. Furtulon (10 micromol/L) gradually reduced the size and number of microvessels over 17 days of culture (100 micromol/L significantly reduced the number by day 4). PD-ECGF/TP (10 ng/ml) and ovarian cancer cyst fluids (2% in medium, v/v) stimulated the production of microvessels. The culture of explants with Furtulon and PD-ECGF/TP or ovarian cancer cyst fluids (from day 1 or day 11 of culture) enhanced the vasoclastic activity of the drug. The effect of Furtulon at the highest dose (1000 micromol/L) or at a lower dose (100 micromol/L) in the presence of ovarian cancer cyst fluid was not reversible after culture day 11.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-1304367,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-1375931,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-1457409,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-1570012,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-1590793,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-1690206,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-1695694,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-1702410,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-2146239,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-2402230,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-2467210,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-2469964,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-2968275,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-2972339,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-6171343,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-7511797,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-7518876,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-7532308,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-7541612,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-7543800,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-7669579,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-7679680,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-7755061,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-8297134,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-8407883,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-8444155,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-8882164,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-9305708,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9811349-9626068
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0002-9440
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
153
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1573-8
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:9811349-Adult,
pubmed-meshheading:9811349-Animals,
pubmed-meshheading:9811349-Antineoplastic Agents,
pubmed-meshheading:9811349-Female,
pubmed-meshheading:9811349-Floxuridine,
pubmed-meshheading:9811349-Humans,
pubmed-meshheading:9811349-Isomerism,
pubmed-meshheading:9811349-Microcirculation,
pubmed-meshheading:9811349-Neovascularization, Pathologic,
pubmed-meshheading:9811349-Ovarian Neoplasms,
pubmed-meshheading:9811349-Prodrugs,
pubmed-meshheading:9811349-Rats,
pubmed-meshheading:9811349-Rats, Wistar,
pubmed-meshheading:9811349-Recombinant Proteins,
pubmed-meshheading:9811349-Thymidine Phosphorylase,
pubmed-meshheading:9811349-Tumor Cells, Cultured
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis: implications for the treatment of ovarian cancer.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynaecology, King's College School of Medicine and Dentistry, London, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
